A single i.v infusion of the investigational ANGPTL3 gene editing agent, VERVE-201cyn 3 mg/kg i.v, reduced ANGPTL3 by more that 90%, and this was maintained for 22 months, according to data from a study of a total of 34 non-human primates.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
